Potential impact of SGLT2 inhibitors on left ventricular diastolic function in patients with diabetes mellitus

Area of Science:

• Cardiology
• Endocrinology
• Pharmacology

Background:

• Diabetes mellitus (DM) is linked to cardiac dysfunction, particularly heart failure with preserved ejection fraction (HFpEF).
• HFpEF, characterized by left ventricular (LV) diastolic dysfunction, lacks effective treatments.
• Hypertension and obesity are significant risk factors for HFpEF in diabetic patients.

Purpose of the Study:

• To review the impact of SGLT2 inhibitors on LV diastolic function in patients with DM.
• To assess the potential of SGLT2 inhibitors in preventing HFpEF development in diabetic individuals.

Main Methods:

• Literature review of clinical trials and studies on SGLT2 inhibitors in diabetic patients.
• Analysis of data regarding SGLT2 inhibitors' effects on glycemic control, weight, blood pressure, and cardiovascular outcomes.
• Evaluation of evidence specifically addressing LV diastolic function and HFpEF prevention.

Main Results:

• SGLT2 inhibitors effectively reduce glycated hemoglobin levels, promote weight loss, and lower blood pressure in type 2 DM patients.
• A recent clinical trial demonstrated cardiovascular benefits of SGLT2 inhibitors in high-risk diabetic patients.
• The specific impact of SGLT2 inhibitors on LV diastolic function in DM remains under investigation.

Conclusions:

• SGLT2 inhibitors offer multifaceted benefits beyond glycemic control for diabetic patients.
• Further research is needed to confirm the efficacy of SGLT2 inhibitors in improving LV diastolic function and preventing HFpEF in this population.
• SGLT2 inhibitors represent a promising therapeutic avenue for managing cardiovascular complications in diabetes.